Neuronetics, Inc. revised revenue guidance for the Full Year 2023. For the period, the company expects total revenue to be between $69.0 million and $73.0 million, increasing the bottom end of the range by $1.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.02 USD | -1.94% | -9.82% | -30.34% |
May. 15 | Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents | CI |
May. 14 | William Blair Upgrades Neuronetics to Outperform From Market Perform | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.34% | 60.6M | |
+7.77% | 218B | |
+10.16% | 189B | |
+26.21% | 151B | |
+32.78% | 113B | |
+1.98% | 64.02B | |
+14.48% | 52.6B | |
+2.92% | 49.85B | |
-6.60% | 37.89B | |
-1.07% | 34.92B |
- Stock Market
- Equities
- STIM Stock
- News Neuronetics, Inc.
- Neuronetics, Inc. Revises Revenue Guidance for the Year Full Year 2023